Guanosine nucleoside analog — selective HBV polymerase inhibitor. First-line oral therapy for chronic HBV with high barrier to resistance + minimal HIV cross-activity. Renal excretion; food reduces F.
Half-Life & Elimination Curve (PO: 5.4d)
Plasma (PO)t½ Decay (5.4d)
0×t½0h100%(10.9 µg/L)
1×t½5.4d50%(5.45 µg/L)
2×t½10.8d25%(2.72 µg/L)
3×t½16.3d12.5%(1.36 µg/L)
4×t½21.7d6.3%(0.681 µg/L)
5×t½27.1d3.1%(0.34 µg/L)
Elimination t½5.4d (PO)
Rate Constant (ke)0.00533 h⁻¹
Time to Peak (Tmax)7.02h
Est. Peak (Cmax)10.9 µg/L
Clearance (CL)0.224 L/h
97% Washout (5×t½)27.1d
Dosing Guidelines
Oral (PO): Typical 0.5 mg (Range: 0.5–1 mg)
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 95% · Volume of Distribution (Vd): 42 L · Absorption (ka): 0.7 h⁻¹ (t½ka ≈ 59m) [PMID 21125816]